We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cardinal (CAH) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Read MoreHide Full Article
The upcoming report from Cardinal Health (CAH - Free Report) is expected to reveal quarterly earnings of $2.37 per share, indicating an increase of 22.8% compared to the year-ago period. Analysts forecast revenues of $64.49 billion, representing an increase of 16.7% year over year.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 0.9% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some Cardinal metrics that are commonly tracked and projected by analysts on Wall Street.
The consensus among analysts is that 'Revenue- Pharmaceutical and Specialty Solutions' will reach $59.01 billion. The estimate indicates a year-over-year change of +16.1%.
The combined assessment of analysts suggests that 'Revenue- Other' will likely reach $1.64 billion. The estimate indicates a change of +28.2% from the prior-year quarter.
Analysts predict that the 'Revenue- Medical Products and Distribution' will reach $3.28 billion. The estimate points to a change of +4% from the year-ago quarter.
According to the collective judgment of analysts, 'Segment profit- Pharmaceutical and Specialty Solutions' should come in at $639.50 million. Compared to the current estimate, the company reported $531.00 million in the same quarter of the previous year.
Based on the collective assessment of analysts, 'Segment profit- Other' should arrive at $157.26 million. Compared to the present estimate, the company reported $118.00 million in the same quarter last year.
Analysts expect 'Segment profit- Global Medical Products and Distribution' to come in at $15.85 million. Compared to the present estimate, the company reported $18.00 million in the same quarter last year.
Shares of Cardinal have experienced a change of +4.5% in the past month compared to the +0.7% move of the Zacks S&P 500 composite. With a Zacks Rank #2 (Buy), CAH is expected to outperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
View the Zacks #1 Rank List
Image: Bigstock
Cardinal (CAH) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
The upcoming report from Cardinal Health (CAH - Free Report) is expected to reveal quarterly earnings of $2.37 per share, indicating an increase of 22.8% compared to the year-ago period. Analysts forecast revenues of $64.49 billion, representing an increase of 16.7% year over year.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 0.9% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some Cardinal metrics that are commonly tracked and projected by analysts on Wall Street.
The consensus among analysts is that 'Revenue- Pharmaceutical and Specialty Solutions' will reach $59.01 billion. The estimate indicates a year-over-year change of +16.1%.
The combined assessment of analysts suggests that 'Revenue- Other' will likely reach $1.64 billion. The estimate indicates a change of +28.2% from the prior-year quarter.
Analysts predict that the 'Revenue- Medical Products and Distribution' will reach $3.28 billion. The estimate points to a change of +4% from the year-ago quarter.
According to the collective judgment of analysts, 'Segment profit- Pharmaceutical and Specialty Solutions' should come in at $639.50 million. Compared to the current estimate, the company reported $531.00 million in the same quarter of the previous year.
Based on the collective assessment of analysts, 'Segment profit- Other' should arrive at $157.26 million. Compared to the present estimate, the company reported $118.00 million in the same quarter last year.
Analysts expect 'Segment profit- Global Medical Products and Distribution' to come in at $15.85 million. Compared to the present estimate, the company reported $18.00 million in the same quarter last year.
View all Key Company Metrics for Cardinal here>>>Shares of Cardinal have experienced a change of +4.5% in the past month compared to the +0.7% move of the Zacks S&P 500 composite. With a Zacks Rank #2 (Buy), CAH is expected to outperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .